About this trial
Unilateral spastic cerebral palsy (USCP) is the most common subtype of cerebral palsy and significantly limits upper limb function. Traditional therapies such as constraint-induced movement therapy (CIMT) and bimanual intensive training offer limited benefits. Pharmacologic treatments often produce behavioral side effects and do not address underlying neuro-plastic deficits. There is an unmet need for safe, effective, non-invasive interventions targeting motor recovery through cortical modulation.
Eligibility criteria
Qualifiers
Children aged 6-17 years with unilateral spastic CP
Wrist extension ≥ 20°, MCP/PIP joints ≥ 10°
Disqualifiers
Any other neurological disorders
An orthopedic condition affecting the participation in UE activities.
Unable to understand the command.
Trial design
Treatments tested in this trial
- Anodal tDCS
- Sham tDCS
Treatment groups
Sponsors and collaborators
Riphah International University
Lead sponsor
King Fahad Specialist Hospital Dammam
Collaborator